Accueil > Actualité
Actualite financiere : Actualite bourse

J&J: exclusive agreement with Karen Pharmaceutical

(CercleFinance.com) - Johnson & Johnson announces that it has entered into an exclusive agreement with Kaken Pharmaceutical for the worldwide development, manufacture and commercialization of the STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD).


This program includes lead candidate KP-723, which will enter Phase 1 trials for AD next year, with potential applications for other Th2-mediated diseases, such as asthma.

Kaken will retain marketing rights in Japan, where Johnson & Johnson may co-promote the product. Kaken will also receive an equity investment from Johnson & Johnson Innovation - JJDC, Inc.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.